387 related articles for article (PubMed ID: 29458780)
1. Immune dysregulation in myelodysplastic syndrome: Clinical features, pathogenesis and therapeutic strategies.
Wang C; Yang Y; Gao S; Chen J; Yu J; Zhang H; Li M; Zhan X; Li W
Crit Rev Oncol Hematol; 2018 Feb; 122():123-132. PubMed ID: 29458780
[TBL] [Abstract][Full Text] [Related]
2. Immune Mechanisms in Myelodysplastic Syndrome.
Glenthøj A; Ørskov AD; Hansen JW; Hadrup SR; O'Connell C; Grønbæk K
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314337
[TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place.
Shallis RM; Chokr N; Stahl M; Pine AB; Zeidan AM
Expert Rev Hematol; 2018 Sep; 11(9):715-726. PubMed ID: 30024293
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
5. The emerging role of immune checkpoint based approaches in AML and MDS.
Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N
Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300
[TBL] [Abstract][Full Text] [Related]
6. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy.
Aggarwal S; van de Loosdrecht AA; Alhan C; Ossenkoppele GJ; Westers TM; Bontkes HJ
Br J Haematol; 2011 Jun; 153(5):568-81. PubMed ID: 21488861
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy.
Kerkhoff N; Bontkes HJ; Westers TM; de Gruijl TD; Kordasti S; van de Loosdrecht AA
Immunotherapy; 2013 Jun; 5(6):621-37. PubMed ID: 23725285
[TBL] [Abstract][Full Text] [Related]
9. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
10. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
Cull AH; Rauh MJ
J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
[TBL] [Abstract][Full Text] [Related]
11. Genetic and Epigenetic Drug Targets in Myelodysplastic Syndromes.
Stankov K; Stankov S; Katanic J
Curr Pharm Des; 2017; 23(1):135-169. PubMed ID: 27697023
[TBL] [Abstract][Full Text] [Related]
12. Emerging biological therapies for the treatment of myelodysplastic syndromes.
Zeidan AM; Stahl M; Komrokji R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
[TBL] [Abstract][Full Text] [Related]
13. [Pathogenesis and treatment of immune dysregulation associated with myelodysplastic syndromes].
Nakajima H
Rinsho Ketsueki; 2023; 64(8):753-763. PubMed ID: 37673628
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
Gañán-Gómez I; Wei Y; Starczynowski DT; Colla S; Yang H; Cabrero-Calvo M; Bohannan ZS; Verma A; Steidl U; Garcia-Manero G
Leukemia; 2015 Jul; 29(7):1458-69. PubMed ID: 25761935
[TBL] [Abstract][Full Text] [Related]
15. Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes.
Ivy KS; Brent Ferrell P
Curr Hematol Malig Rep; 2018 Aug; 13(4):244-255. PubMed ID: 29934935
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
Warlick ED; Miller JS
Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
[TBL] [Abstract][Full Text] [Related]
17. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
[TBL] [Abstract][Full Text] [Related]
18. Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.
Lee P; Yim R; Yung Y; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638574
[TBL] [Abstract][Full Text] [Related]
19. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelodysplastic syndromes (MDS).
Kotsianidis I; Bouchliou I; Nakou E; Spanoudakis E; Margaritis D; Christophoridou AV; Anastasiades A; Tsigalou C; Bourikas G; Karadimitris A; Tsatalas C
Leukemia; 2009 Mar; 23(3):510-8. PubMed ID: 19020538
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
